PN placement: row1 ER proteostasis|Chaperone|HSP70 system|J-domain containing HSP70 cochaperone (mapped→GO:0030544); row2 Extracellular proteostasis|Chaperone|Primarily intracellular, secreted during ER stress (no_mapping) (branches ER, EX)
Consistency: Strong agreement on the core. Notes/YAML describe a soluble ER-lumenal BiP (HSPA5) co-chaperone that stimulates BiP ATPase (GO:0032781 IDA PMID:20335166) and binds misfolded substrates directly via a Cys-rich domain (GO:0051787 IDA PMID:28597544; GO:0140309 holdase IEA). The PN HSP70-cochaperone type fits BiP partnership. One subtlety: the PN type uses GO:0030544 "Hsp70 protein binding," but DNAJB11's partner is the ER HSP70 BiP — biologically Hsp70-family, so consistent. The row2 "secreted during ER stress" PN note aligns with the minor secreted pool the review flags but downgrades; review marks orthology-projected extracellular (GO:0005576) as over-annotated for the core compartment — a defensible nuance, not a contradiction.
PN story / NEW pressure: PN's HSP70-binding assertion is captured (GO:0051787 misfolded protein binding ACCEPT/core; GO:0140309 holdase ACCEPT; core_functions also assert GO:0001671 ATPase activator). Genuine direct-substrate/holdase MF distinguishes ERdj3 from members lacking such data. PN-projected GO:0030544 (verified real) is narrower than the BiP-binding evidence; already captured. No NEW-term pressure (disease/PKD1 maturation = GO:0051604 IMP, captured).
Mapping strategy:GO:0030544 mapping is defensible; ERdj3 has direct BiP-interaction and ATPase-stimulation evidence, so the type-level mapping does NOT over-reach. Row2 extracellular no_mapping is correct.
Evidence alignment: Review's BiP-mechanism PMIDs (18923428, 20335166, 28597544) and disease PMID:29706351 are the substantive set; PN supplies path/title-level context only. No conflict.
Verdict: CONSISTENT — strong direct evidence; GO:0030544 a sound narrower specialization of the verified BiP-cochaperone/holdase MF.